Generium launches omalizumab (Xolair) non-originator in Russia

Biosimilars/News | Posted 11/03/2022 post-comment0 Post your comment

Moscow’s Generium has launched a non-originator biological of omalizumab (Xolair) on the Russian market, the third of Generium’s products using Selexis’ SUREtechnology Platform to reach the market.

Inhaler MD002004 V13J25

Omalizumab is a monoclonal antibody used to treat asthma, as well as nasal polyps and chronic idiopathic urticaria (itchy rash). It is sold under the brand name Xolair by Genentech/Novartis.

On 9 February 2022, Russian firm Generium announced the launch of a non-originator biological of omalizumab in Russia, under the brand name Genolar. Genolar is a recombinant humanized IgG1k monoclonal antibody that binds to free human immunoglobulin E (IgE).

The product is available in Russia for the treatment of persistent atopic bronchial asthma (the most common form of asthma) in patients aged 6 and older and resistant chronic idiopathic urticaria in patients aged 12 and older.

Genolar is manufactured in collaboration with Swiss firm Selexis, whose SUREtechnology Platform can be used in the production of therapeutic recombinant proteins and monoclonal antibodies. The technology uses a Chinese hamster ovary (CHO) cell line to increase the stable expression of recombinant proteins.

Genolar is the third non-originator biological made using Selexis’ platform to reach the market under commercial license agreements between Generium and Selexis, following eculizumab [1] and dornase alfa [2]. It is also the ninth biological product made using the Selexis platform to be marketed overall.

Selexis’ Chief Business Officer Dr Roland Hecht said: ‘Our collaboration with Generium is a proof of Selexis’ ability to provide to our clients stable and scalable high-titer cell lines for cost effective clinical and commercial production, and we’re thrilled to play a continued role in the success of Generium’s programs’.

Generium CEO Daniil Talyanskiy added: ‘Our longstanding partnership with Selexis has brought forth multiple therapeutic solutions in the fields of hematology and pulmonology for the development of CHO-generated biosimilar products. Selexis’ reputation as a leading cell line developer is unparalleled and vital to our success bringing high-quality biologics to the Russian healthcare system’.

Related articles
Non-originator biologicals approved in Russia

BiosanaPharma starts phase I trial for omalizumab biosimilar in Australia

Biosimilars of omalizumab


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View this week’s headline article: Nomenclatura de biológicos y biosimilares en Argentina

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Nomenclatura de biológicos y biosimilares en Argentina

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. Russian approval for non-originator eculizumab []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Mar 11]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. Russian approval for non-originator dornase alfa []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Mar 11]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

Source: Selexis

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010